(Q38025158)

27 August 2017

Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation (English)

1 reference

stem cell transplantation

27 August 2017

1 reference

based on heuristic

inferred from title

hepatic veno-occlusive disease

1 reference

Nancy Kernan

2

0 references

Paul G. Richardson

8

object named as

Paul G Richardson

1 reference

27 August 2017

6

Stephan Grupp

1 reference

27 August 2017

Selim Corbacioglu

1

1 reference

27 August 2017

Leslie Lehmann

3

1 reference

27 August 2017

Joel Brochstein

4

1 reference

27 August 2017

Carolyn Revta

5

1 reference

27 August 2017

Paul Martin

7

1 reference

27 August 2017

1 June 2012

1 reference

Expert Review of Hematology

27 August 2017

1 reference

27 August 2017

5

1 reference

27 August 2017

3

1 reference

27 August 2017

291-302

1 reference

Hepatic Veno-occlusive Disease (Sinusoidal Obstruction Syndrome) After Hematopoietic Stem Cell Transplantation

27 August 2017

1 reference

Transforming growth factor beta-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoetic stem cell transplantation

21 January 2018

1 reference

Veno-occlusive disease of the liver after hemopoietic cell transplantation

21 January 2018

1 reference

The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches

21 January 2018

1 reference

Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome

21 January 2018

1 reference

Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity

21 January 2018

1 reference

Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide

21 January 2018

1 reference

In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis

21 January 2018

1 reference

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe.

21 January 2018

1 reference

Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.

21 January 2018

1 reference

Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome

21 January 2018

1 reference

Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients

21 January 2018

1 reference

Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma

21 January 2018

1 reference

Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients

21 January 2018

1 reference

Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up

21 January 2018

1 reference

Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children

21 January 2018

1 reference

Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia

21 January 2018

1 reference

Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.

21 January 2018

1 reference

Danaparoid as the prophylaxis for hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation in childhood hematological malignancy

21 January 2018

1 reference

A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation

21 January 2018

1 reference

Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation

21 January 2018

1 reference

Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation

21 January 2018

1 reference

Low incidence of hepatic veno-occlusive disease in pediatric patients undergoing hematopoietic stem cell transplantation attributed to a combination of intravenous heparin, oral glutamine, and ursodiol at a single transplant institution

21 January 2018

1 reference

The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo

21 January 2018

1 reference

A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies

21 January 2018

1 reference

Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment

21 January 2018

1 reference

Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist.

21 January 2018

1 reference

The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity

21 January 2018

1 reference

Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease

21 January 2018

1 reference

Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome

21 January 2018

1 reference

Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors

21 January 2018

1 reference

Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias

21 January 2018

1 reference

Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial

21 January 2018

1 reference

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial

21 January 2018

1 reference

Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan.

21 January 2018

1 reference

Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure.

21 January 2018

1 reference

Hepatic veno-occlusive disease: a chemotherapy-related toxicity in children with malignancies

21 January 2018

1 reference

A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer

21 January 2018

1 reference

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

21 January 2018

1 reference

Vascular disorders of the liver

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/EHM.12.18

1 reference

27 August 2017

1 reference